{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:07:03Z","timestamp":1788977223394,"version":"build-2803163510"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100020265","name":"Stan Perron Charitable Foundation","doi-asserted-by":"publisher","award":["000990"],"award-info":[{"award-number":["000990"]}],"id":[{"id":"10.13039\/501100020265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Research Future Fund Investigator Grant","award":["APP1197177"],"award-info":[{"award-number":["APP1197177"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Subcutaneous delivery of antibiotics is a practical alternative to intravenous administration. Ceftriaxone is commonly used for a variety of infections with limited data on the safety and pharmacokinetics of a 2 g subcutaneous dose. This was a prospective, self-controlled cross-over study in 20 stable inpatients receiving ceftriaxone for their infection. Following an intravenous dose, participants received a single dose of 2 g subcutaneous ceftriaxone, in 50 mL normal saline via gravity feed. Capillary dried blood spots were collected at baseline, 1, 2, 4, 8, and 24 hours following the subcutaneous and intravenous doses. Pain scores and infusion site reactions (edema\/erythema) were assessed. Ceftriaxone concentrations were measured using a validated liquid chromatography-tandem mass spectrometry assay. A population pharmacokinetic model was developed using nonlinear mixed-effects modeling. The highest median (interquartile range) pain score within the first 2 hours following infusion of a subcutaneous dose of 2 g ceftriaxone was 2.5 (1\u20134). All participants were pain-free 4 hours after the infusion. The estimated bioavailability was 95.7% (95% bootstrap interval 90.3\u201399.5). Compared with intravenous, subcutaneous administration resulted in lower peak and comparable trough concentrations. The probability of target attainment for free drug concentrations was similar to intravenous administration for most common infections in hospitalized patients. Subcutaneous administration of 2 g ceftriaxone is well tolerated and has a comparable pharmacokinetic profile relative to intravenous dosing in non-critically ill patients with severe infections.<\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>This prospective, self-controlled cross-over design study demonstrates that subcutaneous administration of 2 g ceftriaxone appears safe and well tolerated with a comparable pharmacokinetic profile relative to intravenous dosing in non-critically ill patients with severe infections.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                      <jats:title>CLINICAL TRIALS<\/jats:title>\n                      <jats:p>\n                        This study was registered at\n                        <jats:related-object xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" document-id=\"ACTRN12624000692538\" document-id-type=\"clinical-trial-number\" source-id=\"ANZCTR\" source-id-type=\"registry-name\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12624000692538\">ACTRN12624000692538<\/jats:related-object>\n                        .\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01081-25","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T13:00:30Z","timestamp":1763989230000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Safety, tolerability, and pharmacokinetics of a 2 g subcutaneous dose of ceftriaxone as an alternative to intravenous delivery"],"prefix":"10.1128","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6707-5371","authenticated-orcid":false,"given":"Henco","family":"Nel","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03xba7c91","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Infectious Diseases, Fiona Stanley Fremantle Hospitals Group","place":["Murdoch, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1653-1351","authenticated-orcid":false,"given":"Fionnuala","family":"Murray","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03xba7c91","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Infectious Diseases, Fiona Stanley Fremantle Hospitals Group","place":["Murdoch, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okhee","family":"Yoo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/047272k79","id-type":"ROR","asserted-by":"publisher"}],"name":"Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia","place":["Perth, Australia"]},{"id":[{"id":"https:\/\/ror.org\/047272k79","id-type":"ROR","asserted-by":"publisher"}],"name":"Pharmacy, School of Allied Health, The University of Western Australia","place":["Perth, Australia"]},{"id":[{"id":"https:\/\/ror.org\/047272k79","id-type":"ROR","asserted-by":"publisher"}],"name":"Institute for Paediatric Perioperative Excellence, The University of Western Australia","place":["Perth, Australia"]},{"id":[{"id":"https:\/\/ror.org\/047272k79","id-type":"ROR","asserted-by":"publisher"}],"name":"Centre for Optimisation of Medicines, School of Allied Health, University of Western Australia","place":["Perth, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6525-1084","authenticated-orcid":false,"given":"Matthew","family":"Rawlins","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03xba7c91","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, Fiona Stanley Fremantle Hospitals Group","place":["Murdoch, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1671-6188","authenticated-orcid":true,"given":"Edward","family":"Raby","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03xba7c91","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Infectious Diseases, Fiona Stanley Fremantle Hospitals Group","place":["Murdoch, Australia"]},{"id":[{"id":"https:\/\/ror.org\/027p0bm56","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Microbiology, PathWest Laboratory Medicine, Fiona Stanley Hospital","place":["Murdoch, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Page-Sharp","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02n415q13","id-type":"ROR","asserted-by":"publisher"}],"name":"Curtin Medical School, Curtin University","place":["Bentley, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brioni","family":"Moore","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02n415q13","id-type":"ROR","asserted-by":"publisher"}],"name":"Curtin Medical School, Curtin University","place":["Bentley, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8276-6784","authenticated-orcid":true,"given":"Sam","family":"Salman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/047272k79","id-type":"ROR","asserted-by":"publisher"}],"name":"Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia","place":["Perth, Australia"]},{"id":[{"id":"https:\/\/ror.org\/02n415q13","id-type":"ROR","asserted-by":"publisher"}],"name":"Curtin Medical School, Curtin University","place":["Bentley, Australia"]},{"id":[{"id":"https:\/\/ror.org\/027p0bm56","id-type":"ROR","asserted-by":"publisher"}],"name":"Clinical Pharmacology and Toxicology Unit, PathWest Laboratory Medicine, Fiona Stanley Hospital","place":["Murdoch, Australia"]},{"id":[{"id":"https:\/\/ror.org\/047272k79","id-type":"ROR","asserted-by":"publisher"}],"name":"Medical School, Faculty of Health and Medical Sciences, The University of Western Australia","place":["Crawley, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4334-5351","authenticated-orcid":true,"given":"Laurens","family":"Manning","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03xba7c91","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Infectious Diseases, Fiona Stanley Fremantle Hospitals Group","place":["Murdoch, Australia"]},{"id":[{"id":"https:\/\/ror.org\/047272k79","id-type":"ROR","asserted-by":"publisher"}],"name":"Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia","place":["Perth, Australia"]},{"id":[{"id":"https:\/\/ror.org\/047272k79","id-type":"ROR","asserted-by":"publisher"}],"name":"Medical School, Faculty of Health and Medical Sciences, The University of Western Australia","place":["Crawley, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.01.007"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.035"},{"key":"e_1_3_3_4_2","volume-title":"National antimicrobial utilisation surveillance program: 2022 annual report","author":"SA Health","year":"2024","unstructured":"SA Health. 2024. National antimicrobial utilisation surveillance program: 2022 annual report. Department of Health and Aged Care, Canberra."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2014.03.007"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad505"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X13666170116120828"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afw143"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx477"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae397"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae398"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2019.06.007"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2020.04.035"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa282"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-014-0075-y"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000238342"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz104"},{"key":"e_1_3_3_18_2","unstructured":"Community acquired pneumonia in adults. 2025. Therapeutic guidelines. Melbourne Therapeutic Guidelines Limited. https:\/\/www-tg-org-au.qelibresources.health.wa.gov.au."},{"key":"e_1_3_3_19_2","unstructured":"Peritonitis due to perforated viscus. 2025. Therapeutic guidelines. Melbourne Therapeutic Guidelines Limited. https:\/\/www-tg-org-au.qelibresources.health.wa.gov.au."},{"key":"e_1_3_3_20_2","unstructured":"Directed therapy for native bone or joint infection. 2025. Therapeutic guidelines. Melbourne Therapeutic Guidelines Limited. https:\/\/www-tg-org-au.qelibresources.health.wa.gov.au."},{"key":"e_1_3_3_21_2","volume-title":"Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an abbreviated new drug application","author":"Administration USFaD","year":"2021","unstructured":"Administration USFaD. 2021. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an abbreviated new drug application. FDA Maryland."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01740-15"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00940-18"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.2003.tb01355.x"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24"},{"key":"e_1_3_3_26_2","volume-title":"CLSI guideline M100","author":"CLSI","year":"2024","unstructured":"CLSI. 2024. Performance standards for antimicrobial susceptibility testing. In CLSI guideline M100, 34th ed. Clinical and Laboratory Standards Institute.","edition":"34"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903432900"},{"key":"e_1_3_3_28_2","volume-title":"Pharmacokinetic response after sub-cutaneous administration of ceftriaxone","author":"Shearer TW","year":"2016","unstructured":"Shearer TW. 2016. Pharmacokinetic response after sub-cutaneous administration of ceftriaxone. IDWeek, New Orleans, USA."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2020.03.006"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00874-20"},{"key":"e_1_3_3_31_2","unstructured":"Therapeutic guidelines. 2025. Melbourne Therapeutic Guidelines Limited. https:\/\/www-tg-org-au.qelibresources.health.wa.gov.au."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-025-01041-w"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01081-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01081-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:23:48Z","timestamp":1788974628000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01081-25"}},"subtitle":[],"editor":[{"given":"James E.","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,7]]}},"alternative-id":["10.1128\/aac.01081-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.01081-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"2025-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01081-25"}}